Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral...
Brain
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and...
Restart Life Introduces BrainQ(TM) – A Wholly Owned Brand
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences,...
Phenomix and Mayo Clinic Publish Research Demonstrating Utility of MyPhenome Test for Personalized GLP-1 and Phen-Top Treatment
Published in Cell Metabolism, the Phenomix and Mayo Clinic research shows the MyPhenome™ test can help providers guide obesity treatment by...
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical...
Rose Hill Life Sciences to Spotlight Leading Research Partners at Psychedelic Science 2025
Dr. Gül Dölen, MD, PhD, to share groundbreaking research on how psychedelic compounds can reopen “critical periods” of brain plasticity....
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for...
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
Deep TMS Takes Center Stage with Compelling ResearchBURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ...
Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion
WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer...
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in...
World Precision Instruments and SynVivo Announce Launch of EVOM™ Chip-A Breakthrough Multiplex TEER System Enabling Real-Time Organ-on-Chip Monitoring
SARASOTA, Fla., June 10, 2025 /PRNewswire/ -- World Precision Instruments (WPI), the global leader in transepithelial electrical resistance (TEER) technology, in...
Chen Institute Opens Public Registration for Symposium on AI Accelerated Science
Join Us in San Francisco, October 27-28! REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- The Tianqiao and Chrissy Chen...
Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized dosing and therapeutic support for...
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025...
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with...
Unisys Innovation Program Announces the Winners of Its 16th Annual Competition
Top three teams recognized for ideas to create sustainable electric mobility, tumor diagnostics accuracy and remote neurological monitoring BENGALURU, India,...
Restart Life Introduces BrainBalls(TM) Product Line
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or...